Neurologist joins Geisinger staff
,
DANVILLE, Pa. – Muhammad Malik, M.D., a board-certified and fellowship-trained neurologist specializing in neuroimmunology and neuroinfectious disease has joined the Geisinger Neuroscience staff.
Dr. Malik completed a clinical neuroimmunology and neuroinfectious disease fellowship at Johns Hopkins School of Medicine in 2019 and completed his residency at Geisinger Medical Center in 2018. He received his medical degree from the Army Medical College in Pakistan and completed two research post-doctoral fellowships at Harvard Medical School in neuroimmunology and neuro-ophthalmology.
Dr. Malik is certified by the American Board of Psychiatry and Neurology. He will see patients in Danville, Bloomsburg, Williamsport and Wilkes-Barre. He is fluent in English, Arabic, Hindi and Urdu.
Dr. Malik completed a clinical neuroimmunology and neuroinfectious disease fellowship at Johns Hopkins School of Medicine in 2019 and completed his residency at Geisinger Medical Center in 2018. He received his medical degree from the Army Medical College in Pakistan and completed two research post-doctoral fellowships at Harvard Medical School in neuroimmunology and neuro-ophthalmology.
Dr. Malik is certified by the American Board of Psychiatry and Neurology. He will see patients in Danville, Bloomsburg, Williamsport and Wilkes-Barre. He is fluent in English, Arabic, Hindi and Urdu.
About Geisinger
Geisinger is committed to making better health easier for the more than 1 million people it serves. Founded more than 100 years ago by Abigail Geisinger, the system now includes 10 hospital campuses, a health plan with more than half a million members, a research institute and the Geisinger College of Health Sciences, which includes schools of medicine, nursing and graduate education. With more than 25,000 employees and 1,700+ employed physicians, Geisinger boosts its hometown economies in Pennsylvania by billions of dollars annually. Learn more at geisinger.org or connect with us on Facebook, Instagram, LinkedIn and Twitter.
